1. Home
  2. HURA
  3. HURA News

Latest TuHURA Biosciences Inc. Common Stock (HURA) News on October 8, 2025

HURA

MT Newswires

3 months ago

TuHURA Biosciences Launches Phase 3 Study of Potential Cancer Immunotherapy Drug

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
HURA

PR Newswire

3 months ago

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

HURA

MT Newswires

3 months ago

TuHURA Biosciences Shareholders Approve Merger With Kineta; Shares Rise

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
HURA

PR Newswire

3 months ago

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

HURA

MT Newswires

4 months ago

Brookline Capital Initiates Coverage on TuHURA Biosciences With Buy Rating, $9 Price Target

HURA

MT Newswires

4 months ago

TuHURA Says FDA Lifts Partial Hold on Skin Cancer Study

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
HURA

PR Newswire

4 months ago

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy
HURA

PR Newswire

4 months ago

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
HURA

PR Newswire

4 months ago

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

HURA

Zacks Small Cap Research

5 months ago

HURA: First Quarter 2025 Results

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
HURA

PR Newswire

5 months ago

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference
HURA

PR Newswire

5 months ago

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)
HURA

PR Newswire

5 months ago

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

HURA

MT Newswires

5 months ago

TuHURA Biosciences Reports Cancer Immunotherapy Safe, Well Tolerated in Clinical Trial

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
HURA

PR Newswire

5 months ago

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts?
HURA

Insider Monkey

6 months ago

Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts?

HURA: 2024 Financial Results
HURA

Zacks Small Cap Research

6 months ago

HURA: 2024 Financial Results

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting
HURA

PR Newswire

6 months ago

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
HURA

PR Newswire

6 months ago

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

Is TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans?
HURA

Simply Wall St.

6 months ago

Is TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans?

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
HURA

PR Newswire

6 months ago

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors
HURA

ACCESS Newswire

7 months ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
HURA

ACCESS Newswire

7 months ago

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
HURA

ACCESS Newswire

8 months ago

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

HURA: Initiating an Immune Response
HURA

Zacks Small Cap Research

8 months ago

HURA: Initiating an Immune Response

When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)?
HURA

Simply Wall St.

9 months ago

When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)?

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
HURA

ACCESSWIRE

10 months ago

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
HURA

ACCESSWIRE

10 months ago

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
HURA

ACCESSWIRE

a year ago

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event
HURA

ACCESSWIRE

a year ago

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

Share on Social Networks: